A randomized, double-blind, double-dummy, parallel group, phase 3 efficacy and safety study of CGT-2168 [clopidogrel/omeprazole] compared with clopidogrel to reduce upper gastrointestinal events including bleeding and symptomatic ulcer disease.

Trial Profile

A randomized, double-blind, double-dummy, parallel group, phase 3 efficacy and safety study of CGT-2168 [clopidogrel/omeprazole] compared with clopidogrel to reduce upper gastrointestinal events including bleeding and symptomatic ulcer disease.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Clopidogrel/omeprazole (Primary) ; Aspirin; Clopidogrel
  • Indications Acute coronary syndromes; Embolism and thrombosis; Gastrointestinal haemorrhage
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms COGENT; COGENT-1
  • Most Recent Events

    • 30 Apr 2016 Results of post-hoc analyses (n=3759) published in the American Journal of Medicine.
    • 16 Mar 2016 Results (n=3752) published in the Journal of the American College of Cardiology
    • 06 Oct 2010 Results published in NEJM.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top